Study on Optimizing the Treatment of Patients With Acute Myeloid Leukemia Based on Early Peripheral Blood Minimal Residual Disease
NCT07023588
·
clinicaltrials.gov ↗
PHASE2
Phase
RECRUITING
Status
70
Enrollment
OTHER
Sponsor class
Conditions
Acute Myeloid Leukemia (AML)
Interventions
DRUG:
Venetoclax
Sponsor
Yehui Tan